Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8818888 | 0.89 | GPR119 (0.44) | GPR119IRAK4NSD2FPR2USP30 | |
| SCHEMBL7350000 | 0.80 | CFD (0.37) | IRAK4JAK2JAK1FPR2 | |
| SCHEMBL7350588 | 0.79 | GPR119 (0.49) | GPR119FPR2USP30 | |
| SCHEMBL7369656 | 0.76 | GSK3B (0.38) | — | |
| SCHEMBL29122756 | 0.75 | USP30 (0.45) | GPR119FPR2USP30 | |
| SCHEMBL29122133 | 0.75 | USP30 (0.45) | GPR119FPR2USP30 | |
| SCHEMBL29122129 | 0.75 | USP30 (0.45) | GPR119FPR2USP30 | |
| SCHEMBL8820197 | 0.75 | GPR119 (0.46) | GPR119NSD2FPR2USP30 | |
| SCHEMBL7336346 | 0.74 | GPR119 (0.64) | GPR119FPR2USP30 | |
| SCHEMBL29121680 | 0.74 | USP30 (0.46) | GPR119FPR2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912555-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997049699-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |